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Purpose: To investigate the role of Tafazzin (TAZ) protein in regulating the proliferation of normal human conjunctiva
epithelial cells and epithelial cells from pterygium tissue.
Methods: Conjunctiva epithelial cells were cultured in keratinocytes growth medium and treated with transformation
growth factor β (TGFβ) to analyze the expression and translocation of TAZ protein by immunostaining and BrdU analysis.
Immortalized conjunctiva epithelial cells (NHC) were treated with TGFβ, targeting siRNA, TGFβ receptor antibody or
TGFβ receptor inhibitor, to study the involvement of TAZ and TGFβ signaling pathway in conjunctiva cell proliferation
by cell adhesion assay. Conjunctiva tissues from a normal human eye and an eye with pterygium disease were collected
for histological analyses and western blot to evaluate the TAZ protein expression in vivo.
Results: TAZ expression was upregulated in mitotic conjunctiva epithelial cells, proliferating conjunctiva epithelial cells,
TGFβ treated conjunctiva epithelial cells and human pterygium epithelium. TAZ siRNA induced less conjunctiva epithelial
cell growth. Moreover, TGFβ receptor antibody and TGFβ receptor inhibitor rescued this anti-proliferative effect of
TAZ siRNA.
Conclusions: TAZ is involved in human conjunctiva epithelial cells proliferation via regulating TGFβ signaling pathway.
Pterygium is a common ocular disease characterized by
a fibrovascular membrane advancing on the corneal surface.
Pterygium  is  caused  by  the  abnormal  growth  and
differentiation  of  the  conjunctival  epithelial  cells  of  the
corneal  limbus  [1,2].  Previous  studies  have  shown  an
overexpression  of  transforming  growth  factor β  ( TGFβ)
signaling  in  pterygia  tissue  when  compared  with  normal
conjunctiva.  Therefore,  the  proliferation  of  conjunctiva
epithelium in pterygium may be attributed to the activities of
TGFβ.
TGFβ regulates important biologic functions, including
cell growth, differentiation, migration and apoptosis, which
have been extensively investigated and reviewed [3-5]. In the
mature  mammalian  epithelium,  TGFβ  signal  induces  cell
cycle arrest, apoptosis, cell adhesion and cytokine secretion
[6-8].  Biologic  signals  for  TGFβ  are  transduced  through
transmembrane serine/threonine kinase receptors to a family
of  intracellular  mediators  known  as  mothers  against
decapentaplegic homolog (Smad) proteins [9]. Smad proteins
are activated to either propagate or inhibit the TGFβ signal by
interacting  with  other  modulators.  The  TGFβ  superfamily
receptors have been found to have a distinct and specific
distribution  in  the  conjunctiva  epithelium,  indicating  that
conjunctiva epithelial cells respond to TGFβ cytokine and that
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TGFβ may have important autocrine and/or paracrine roles in
the growth and metabolism of ocular tissues in vivo [10,11].
Tafazzin (TAZ) protein is a transcriptional co-activator,
which  contains  a  14–3-3  binding  fragment,  a  single  WW
domain and a PDZ-binding motif [12]. Mutations of TAZ
protein have been reported to be related to a dysfunction of
caspase activities in mammalian cells [13,14]. Recently, TAZ
was reported to be essential in regulating hippo pathway and
β-catenin/wnt  pathway  during  organ  size  control,  tissue
regeneration and stem cell self-renewal [15-17]. Additionally,
the WW domain of the TAZ protein was found to be able to
bind with the PPXY motif of the transcription factor runt-
related transcription factor 2 (RUNX2 [18-20]. This opens up
the  possibilities  that  other  PPXY  sequences  containing
transcription factors, such as myocyte enhancer factor 2B
(MEF2B), Smad, and sex determining region Y-box (SOX)
family molecules, are also possible binding candidates of TAZ
[20]. Subsequently it was found that TAZ binds with Smad
2/3 to shuttle the TGFβ stimulated nucleus translocation of
Smad  proteins  to  regulate  human  embryonic  stem  cell
proliferation  [21].  Currently,  there  are  no  reports  in  the
literature regarding the study of TAZ in ocular tissues.
In  the  present  study,  we  sought  to  investigate  the
involvement of TAZ protein and TGFβ signaling in regulating
conjunctival epithelial cell proliferation. Moreover, we aimed
to investigate the expression and location of TAZ protein in
human  conjunctiva  epithelium  and  epithelium  from
pterygium samples.
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Human conjunctiva and pterygium cell isolation and culture:
All  human  tissue  related  studies  were  performed  in
accordance with the tenets of the Declaration of Helsinki and
the study protocol was approved by the Institutional Review
Board of the Singapore Eye Research Institute and Singapore
National Eye Centre. Informed written consent was obtained
from each participant.
Pterygium  biopsies  were  collected  from  patients
undergoing routine surgery for pterygium removal. A small
piece of normal conjunctiva (1×3 mm) was removed from the
super bulbar region, 10–15 mm from the limbus. For cell
isolation and culture, tissue biopsies were briefly rinsed with
phosphate  buffer  saline,  followed  by  stirring  in  buffer
containing 30 mM HEPES, 4 mM glucose, 3 mM KCL, 1 mM
Na2HPO4 and 1.2% dispase. Epithelial cells were collected by
centrifugation and cultured in serum-free keratinocyte growth
medium (KGM) with supplements of bovine pituitary and
epithelial  growth  factor  (EGF).  For  TGFβ  stimulation
experiments,  conjunctiva  epithelial  cells  were  cultured  in
KGM  medium  without  supplements  for  2  days  before
treatment.
5-Bromo-2’-deoxyuridine  (BrdU)  assay:  Immortalized
normal human conjunctiva cells (NHC cells) were cultured in
Dulbecco’s modified eagle medium (DMEM) supplemented
with 10% fetal calf serum and grown on round shape glass
coverslips, which were inserted on the bottom of the 24 well
plate dishes. BrdU (10 µm) was added into the culture medium
for 24 h before fixation with 4% paraformaldehyde. After
treatment with 2 N hydrochloric acid (HCL) for 15 min, cells
were stained with monoclonal anti-BrdU (Sigma, St. Louis,
MO) and polyclonal anti-TAZ (Santa Cruz Biotechnology,
Santa Cruz, CA). 4',6-diamidino-2-phenylindole (DAPI) was
applied in the mounting medium as a nucleus counter stain.
Images of the cells after staining were taken by LSM510
confocal microscope (Carl Zeiss, Jena, Germany) and the
fluorescent intensity of the defined area was measured by
Image J (NIH) software. Briefly, the staining pictures were
converted into monochrome images and measured with the
intensity tools. The intensities of the cells at cell cycle resting
stage or TGFβ non-treated cells were defined as “1.” The
fluorescence intensities of testing cells were normalized to the
readings of cells at control group and defined as “relative
fluorescence intensity.”
SiRNA transfection and commassie brilliant blue staining:
TAZ siRNA (Santa Cruz) is a combination of three siRNA
sequences targeting the human TAZ gene (NM_013595): A;
GUA CUU CCU CAA UCA CAU Att, UAU GUG AUU
GAG GAA GUA Ctt: B; CUA GGA AGG CGA UGA AUC
Att, UGA UUC AUC GCC UUC CUA Gtt: C; GGA UGU
AGC CAU GAC CUU Att, UAA GGU CAU GGC UAC AUC
Ctt.  Both  TAZ  siRNA  and  mock  siRNA  (Santa  Cruz
Biotechnology) were transiently transfected into NHC cells
with  lipofectamine  2000  (Invitrogen,  Carlsbad,  CA)  as  a
carrier,  according  to  the  protocol  provided  by  the
manufacturer.  NHC  cells  were  collected  at  24  h  after
transfection for further processing. For cell density analysis,
NHC cells were stained with 0.5% commassie brilliant blue
before scanning. The scanning pictures were converted into
monochrome  images  and  measured  with  the  intensity
measurement tools of Image J (NIH) software. The averaged
intensities of the scanning images for non-treated specimens
were defined as “1.” The intensities of the scanning images
for treated specimens were normalized to the readings of
control group and defined as “relative cell density.”
Transcriptional response assay: For the luciferase reporter
assay, NHC were grown on Costar® white 96-well dish and
transfected with 10–4-cyclin E-lux cDNA (addgene plasmid
8458) with lipofectamineTM 2000 (Invitrogen). 10–4-cyclin
E–lux  (50  ng)  was  transfected  into  NHC  cells  with  a
combination of mock siRNA or siTAZ. Luciferase activity in
cell lysate was measured using the Bright-GloTM luciferase
assay system (Promega, Madison, WI) in a TecanTM Xfluor 4
Geniospro  V4.5  luminometer  (Tecan,  Seestrasse,
Männedorf). Data were collected from 3 repeats.
Immunofluorescence:  NHC  cell  line  or  primary  human
conjunctiva epithelial cells after treatment were fixed with 4%
paraformaldehyde  and  washed  by  phosphate  buffer  saline
with 0.2% triton-x 100. Normal conjunctiva or pterygium
tissue after dissection was fixed with 4% paraformaldehyde
before cryopreserving with 20% sucrose. Eight µm thickness
sections  were  collected  with  a  cryostat  (Leica,  Wetzlar,
Germany).  The  primary  antibodies  for  immunostaining
include polyclonal anti-TAZ and anti-Smad4 (Cell signaling
Technology, Danvers, MA). Secondary antibodies include
Alexflour 488 or Alexflour 555 conjugated goat anti-mouse
or goat anti-rabbit secondary antibody (Invitrogen). Images of
the specimens after staining were taken by LSM510 confocal
microscope (Carl Zeiss, Jena, Germany).
Immunoblotting: Conjunctiva epithelial cells were plated on
a 9 cm × 9 cm culture dish till 80% to 90% confluence. After
treatment, the cells were collected and lysed in RIPA buffer
(50  mM  Tris-HCL,  1  mM  EDTA,  0.25%  sodium
deoxycholate,  150  mM  sodium  chloride,  and  1%  NP-40)
containing 1 mM DTT, protease inhibitor cocktail, 1 mM
Na3VO4, and 1 mM PMSF. A total of 30 µg of each protein
was loaded for SDS–PAGE gel analysis. Primary antibodies
for western blot were anti-TAZ (Santa Cruz Biotechnology)
and anti-β-actin (Sigma, St. Louis, MO).
Secondary  antibodies  for  western  blot  included
horseradish peroxidase conjugated sheep anti-mouse/rabbit
IgG (GE Healthcare, Buckinghamshire, England).
RESULTS
We  performed  TAZ  immunostaining  on  primary  normal
human conjunctiva epithelial cells to investigate the role of
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1403TAZ  protein  in  cell  proliferation.  Nucleus  DAPI
counterstaining was applied to indicate the cell dividing stage.
We observed that the fluorescence intensity of TAZ protein
was strongly upregulated in dividing cells compared with that
of neighbor cells at the resting stage (Figure 1A). A total of
120 cells from three independent repeats were collected for
analysis. The averaged fluorescence intensity of TAZ protein
in mitotic cells was around 5.2±0.4 fold higher than that of the
resting  cells  (Figure  1B).  Upregulation  of  TAZ  protein
expression was also observed in proliferating cells during
other cell cycle phases, which were reflected by the DAPI
staining pattern (Figure 2). We treated conjunctiva epithelial
cells with 2N HCL for 15 min (Figure 2A) or 40 min (Figure
2B) to allow for permeabilization of TAZ antibody. We found
that  in  dividing  conjunctiva  keratinocyte,  TAZ  protein
concisely co-localizes with DAPI, an indicator for DNA. We
did  transcriptional  response  assay  to  determine  the
involvement of TAZ in cell cycling/proliferation, which was
accessed  by  transcriptional  activities  of  10–4-cyclin  E
promoter.  10–4-cyclin  E  promoter  is  required  for  the
mammalian cell transition from G1 to S phase. TAZ siRNA
induced  significant  less  transcriptional  activities  of  10–4-
cyclin E promoter in NHC cells and this effect is dosage
dependent (Figure 2C).
BrdU analysis was performed to further examine whether
TAZ  protein  is  upregulated  in  proliferating  conjunctiva
epithelial cells. We observed that in BrdU positive cells, TAZ
protein was found clustering in the nucleus of the cells, while
in  cells  that  were  BrdU  negative,  TAZ  protein  was
predominantly  expressed  in  the  cytoplasm  (Figure  3).
Moreover, the fluorescence intensity of TAZ signal in BrdU
positive cells was also observed to be much higher than that
of BrdU negative cells. This result is consistent with our
previous observation that TAZ protein was highly upregulated
during epithelial cell division and proliferation; therefore, the
activation  and  translocation  of  TAZ  protein  are  closely
associated with epithelial cell proliferation.
TAZ regulates TGFβ signaling: It was recently reported that
TAZ is responsive to TGFβ cytokine, forming a complex with
Smad protein at the cytoplasm, which facilitated the nucleus
translocation of Smad proteins in human embryonic stem cells
[21]. In our study, we aimed to investigate whether the TAZ
Figure  1.  TAZ  protein  expression  is
upregulated  in  mitotic  cells.  A:
Conjunctiva  epithelial  cells  were
stained with anti-TAZ antibody. TAZ:
red; DAPI: blue. Higher magnification
image  is  shown  in  lower  row.
Immunofluorescence  signal  of  TAZ
protein  is  significantly  higher  in  a
dividing  cell  (white  arrow)  compared
with that of a neighbor cell (white star).
Scale  bar  is  20  µm.  B:  Relative
quantitative red fluorescence intensity
of  total  30  dividing  cells  and  90
neighbor  cells  were  measured.  Data
were represented as mean±se ** p<0.05,
one-way ANOVA (ANOVA).
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1404signal in human conjunctiva epithelial cells is also responsive
to TGFβ. Our data showed that the fluorescence intensity of
endogenous TAZ signal in epithelial cells that were treated
with TGFβ is higher than that of cells without TGFβ treatment
(Figure 4A). Smad4 staining was simultaneously performed
as an indicator of the cells that were responsive to TGFβ. The
relative quantitative fluorescence intensity in the nucleus of
the epithelial cells was measured (Figure 4B). A total of 100
cells from three repeated experiments were analyzed. We
found that after TGFβ treatment, fluorescent intensity of TAZ
protein in the cell nucleus is about 2.5±0.3 times higher than
that  of  untreated  cells  (Figure  4B).  Western  blot  analysis
further  confirmed  that  the  TAZ  protein  expression  was
upregulated in TGFβ treated cells (Figure 4C). Altogether,
these  results  indicate  that  TAZ  protein  is  responsive  to
TGFβ stimuli in human conjunctiva epithelial cells.
TAZ regulates conjunctiva epithelial cell proliferation via
TGFβ signaling: We initially did western blot and commassie
brilliant blue staining to confirm the effect of TAZ siRNA.
Western blot images (Figure 5A) indicated that there was
down-regulation  of  TAZ  gene  expression  by  TAZ  siRNA.
Commassie  brilliant  blue  staining  images  (Figure  5B)
indicated that TAZ silencing induced lower conjunctiva cell
attachment and cell growth. We then sought to investigate
whether  TAZ  regulates  the  growth  rate  of  NHC  cells  by
interacting with a TGFβ signal. NHC is an immortalized cell
line, which was derived from the normal human conjunctiva
epithelium and shared a lot of characteristics with primary
conjunctiva epithelial cells [22]. TGFβ receptor I antibody
was added to block the signal transduction of TGFβ. We found
that silencing of the TAZ gene significantly suppressed the
proliferation rate of NHC cells (Figure 6A, “a”). However,
this suppression was rescued by the treatment of anti-TGFβ
Receptor I antibody (10 µg/ml, Figure 6A, “b”). Our data
indicated that TAZ regulated the epithelial cell proliferation
by interacting with the TGFβ signal. NHC cells were also
Figure  2.  TAZ  protein  expression  is
upregulated in mitotic cells at various
cell cycle stage. A and B: Conjunctiva
epithelial  cells  were  stained  by  TAZ
(red) after treating with hydrochloride
for  15  min  (A)  or  40  min  (B).
Counterstaining with DAPI (blue) was
performed  as  an  indicator  of  cells  at
different cell cycle stages. White arrows
indicate  the  cells  which  were
undergoing cell division. Scale bar is 20
µm. C: TAZ siRNA induced less 10–4-
cyclin  E  promoter  transcription
activities in NHC cell lines in a dosage
dependent  manner.  Data  have  been
represented  as  mean±se  from  three
replicates.
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1405treated with the specific TGFβ receptor inhibitor, SB431542.
Silencing of the TAZ gene suppressed the cell growth rate of
NHC  cells  and  this  effect  was  significantly  rescued  by
SB431542 (10 nm, Figure 6B).
Expression of TAZ in pterygium tissue: We then examined the
expression  of  TAZ  protein  in  human  normal  conjunctiva
epithelium  and  pterygium  conjunctiva  epithelium.  TAZ
protein was blotted from the total lysate of the epithelial layers
of  conjunctiva  tissues.  We  found  that  TAZ  expression  in
pterygium tissue was much higher than that of normal tissue
(Figure 7A). Intensity of the blotting bands showed that the
expression level of TAZ protein in pterygium epithelium is
around 10 times higher than that of the normal conjunctiva
tissue  (Figure  7B).  Immunostaining  of  the  pterygium
conjunctiva  tissue  revealed  that  TAZ  protein  is  highly
clustering in the epithelial layer of conjunctiva tissue (Figure
7C).
DISCUSSION
The TGFβ signaling pathway controls a diverse set of cellular
activities  and  is  regulated  by  various  receptors  and
transcription factors. Here, we addressed the role of TAZ in
the regulation of conjunctiva epithelial cell proliferation by
interacting with the TGFβ signaling pathway. TAZ protein
expression  was  found  to  be  upregulated  in  the  mitotic
conjunctiva epithelial cells and pterygium epithelium, which
is a novel observation and has never been reported before.
Moreover,  TGFβ  receptor  antibody  and  TGFβ  receptor
inhibitor partially rescued cell growth inhibition, which was
induced by TAZ siRNA. Hence, TAZ is involved in regulating
conjunctiva cell proliferation via the TGFβ pathway.
Previous  studies  revealed  that  Smad  family  protein
functions  by  directly  binding  with  DNA  promoters  and
consensus fragments resulting in the activation of target genes
[23-25]. A growing number of DNA binding factors, such as
Fas-activated  serine/threonine  kinase  (FAST),  activator
protein 1 (AP1)-containing elements and transcription factor
E (TFE), as well as TAZ, have been identified to facilitate the
Smad-induced gene activation [26]. In our study, we found
the co-localization of TAZ protein with DAPI signal in mitotic
cells,  which  indicated  that  TAZ  is  related  to  cell  cycle
regulation and TAZ protein is a transcriptional factor that may
act by binding with Smad and DNA promoters or consensus
after stimulation.
Several WW domain containing ubiquitin ligases have
been identified to negatively regulate the TGFβ signal by
Figure 3. TAZ protein clusters at the
nucleus of proliferating epithelial cells.
Conjunctiva  epithelial  cells  were
labeled for BrdU (red) and TAZ (green),
DAPI was applied as nucleus counter
staining  dye  (blue).  White  arrows
indicate a BrdU positive epithelial cell
also stained by high intensity of TAZ
protein. Scale bar is 20 µm.
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1406targeting and degradation of Smad family proteins [26,27].
The  HECT-type  WW  domain  containing  ubiquitin  ligase,
Smurf2, was reported to down-regulate the TGFβ signal by
binding with the proline-rich domain of Smad7 and form a
complex  with  TGFβ  receptors  [28-30].  Smurf2  was  also
reported to degrade the receptor binding Smad protein, Smad
1 [31]. Another receptor binding Smad protein, Smad2, was
also found to be able to form assembly with Smurf2 and be
degraded by Smurf2 [32,33], while the co-Smad, Smad4, can
be  targeted  indirectly  by  Smurf2  and  be  degraded
simultaneously  with  R-Smad  and  I-Smad  [34].  The  WW
domain containing protein, TAZ, shares a similar structure
with smurf2 [19]. TAZ functions by binding with Smad family
proteins and TAZ antagonised the TGFβ induced cell growth
Figure 4. TAZ is responsive to TGFβ
signal in conjunctiva epithelial cells. A:
Fluorescent  signals  of  TAZ  protein
(green)  and  smad4  (red)  were
upregulated after TGFβ treatment. Scale
bar is 20 µm. B: Relative quantitation of
the green fluorescent intensity of TAZ
protein. Data were represented as mean
±se, * p<0.01, ANOVA. C: Cell lysate
of the epithelial cells with or without
TGFβ treatment were blotted by anti-
TAZ. Expression of TAZ protein was
upregulated in TGFβ treated cells.
Figure  5.  TAZ  siRNA  induced  a
depletion  of  TAZ  protein  in  NHC
keratinocytes. A: Anti-TAZ blotting of
the NHC cells which were treated by 15
PM  TAZ  siRNA  or  mock  siRNA.  B:
Pictures  show  representative  fields  of
cells treated by mock or TAZ targeting
siRNA.  NHC  cells  were  stained  by
commassie brilliant blue. Scale bar is 10
um.
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1407inhibition. Altogether, these findings indicate that TAZ and
smurf family proteins probably serve separate but perhaps
overlapping functions. Hence, TAZ may be an ubiquitin co-
activator that negatively regulates the TGFβ/Smad signaling
pathway to regulate mammalian cell proliferation.
Many tumor cells are resistant to TGFβ induced apoptotic
effect. The mechanisms are reported to be associated with the
mutation  of  the  receptors  or  components  of  the  Smad
pathways [35,36]. TGFβ has a biphasic role in tumor genesis.
In the initial phases it acts as a tumor suppressor, whereas
during the late phases it has been shown to function as a tumor
promoter  [4].  TGFβ  stimulates  the  de-differentiation  of
epithelial  cells  into  malignant  invasive  and  metastatic
fibroblastic cells. This procedure was regulated by various co-
factors. Recently, Yes-associated protein 1 (YAP1), a protein
that shares its homological structure with TAZ, was reported
to play a critical role in regulating the expression of cancer
gene tumor protein 73 (p73) and in regulating tumor cell
migration  [37].  These  reports  indicate  that  other
transcriptional co-factors, such as TAZ, may also interact with
the  TGFβ  signal  and  regulate  cancer  cell  migration  and
invasion. In our studies, we found that TAZ expression was
upregulated in the epithelial tissue with pterygium disease
compared with that of the normal conjunctiva tissue (Figure
6).  The  pterygium  is  studied  as  a  benign  tumor  whose
genotype is highly associated with the mutation of tumor
suppressor gene p53 [38,39]. Our findings at least indicated
that TAZ is possibly involved in the pathology of pterygium
Figure 6. TGFβ receptor antibody and
TGFβ  receptor  inhibitor  rescued  the
effect of TAZ siRNA on cell growth. A:
NHC  cells  were  treated  with  TGFβ
receptor type I antibody together with
mock siRNA or TAZ siRNA. Relative
cell  density  was  analyzed  from  three
replicates. a: a significant reduction of
cell density after TAZ siRNA treatment.
“b”:  the  cell  growth  inhibition  was
rescued by TGFβ receptor I antibody
treatment. B: NHC cells were treated
with  TGFβ  receptor  inhibitor
(SB431542) together with mock siRNA
or  TAZ  siRNA.  Relative  cell  density
was  analyzed  from  three  replicates.
“a’”:  a  significant  reduction  of  cell
density  after  TAZ  siRNA  treatment.
“b’”: cell growth inhibition was rescued
by SB431542. Data were represented as
mean±se (p<0.05).
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1408by regulating the TGFβ signal. Further mechanism and in vivo
studies are necessary to clarify this.
In  conclusion,  we  found  that  TAZ  regulates  human
conjunctiva epithelial cell proliferation via inhibiting TGFβ
signaling.  We  also  found  that  TAZ  is  upregulated  in
pterygium tissue. This finding provides an important clue to
the  mechanisms  of  TGFβ  signaling  in  the  regulation  of
conjunctiva  cell  proliferation  and  pterygium  progression.
Furthermore, TAZ may also play an important role in the
pathogenesis of other ocular diseases, such as TGFβ related
fibrogenesis  diseases,  corneal  wound  healing  and  protein
aggregation.
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images show that the TAZ protein is
expressed  at  the  epithelial  layer  of
conjunctiva tissue. Scale bar is 10 µm.
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